

**BOSTON SCIENTIFIC CORPORATION
BUSINESS ASSOCIATE AGREEMENT**

THIS BUSINESS ASSOCIATE AGREEMENT (“BA Agreement”) is entered into by and between Boston Scientific Corporation (“**Boston Scientific**”), with offices at 300 Boston Scientific Way, Marlborough, MA 01752 and the entity or individual (“**Provider**”) to whom Boston Scientific makes available patient reimbursement assistance by facilitating the preparation and submission of requests for coverage determinations, prior authorizations, pre-certifications and appeals of denied claims, relating to Boston Scientific’s own medical technologies, as allowed under the AdvaMed Code of Ethics on Interactions with Health Care Professionals (“**Reimbursement Assistance**”). These services require the exchange of information about patients that is protected by the Health Insurance Portability and Accountability Act of 1996 (“**HIPAA**”) as applicable to Business Associates, as well as any amendments or additions thereto, including amendments made by the HITECH Act and GINA (defined below). The Provider is a “Covered Entity” as that term is defined in HIPAA, and the parties desire to establish the responsibilities of both parties regarding HIPAA-covered information and to meet their obligations under HIPAA.

- 1. Definitions.** Unless otherwise specified in this BA Agreement, all capitalized terms used in this BA Agreement not otherwise defined have the meaning set forth in HIPAA, as amended from time to time.
 - 1.1 “Breach Notification Rule”** means the breach notification regulations at 45 CFR Part 160 and 45 CFR Part 164, Subpart D, as they exist now or as they may be amended.
 - 1.2 “Compliance Date” or “Compliance Dates”** shall mean the date established by HHS or the United States Congress for effective date of applicability and enforceability of HIPAA and the HITECH Act.
 - 1.3 “Data Aggregation”** shall have the meaning assigned to such a term in 45 CFR § 164.501, and includes, but is not limited to, combining Phi created or received to permit data analysis services for Provider as specified in a written agreement and consistent with this BAA.
 - 1.4 “Designated Record Set”** shall have the meaning assigned to such term in 45 CFR § 164.501, but shall be limited to any item, collection or grouping of PHI maintained, created, or received by or for Provider.
 - 1.5 “Destruction”** means the use of a technology or methodology by which the media on which the PHI is stored or recorded has been shredded, destroyed, cleared, or purged, as appropriate, such that the PHI cannot be read, retrieved, or otherwise reconstructed. Redaction is inadequate for the purposes of destruction.
 - 1.6 “Electronic PHI” or “E PHI”** shall mean Electronic Protected Health Information, as defined in 45 CFR § 160.103, limited to the information received from or created or received on behalf of Provider by Boston Scientific solely for the purposes of Boston Scientific’s provision of Reimbursement Assistance in its capacity as a Business Associate.
 - 1.7 “Encryption”** shall mean a technology or methodology that utilizes an algorithmic process to transform data into a form in which there is a low probability of assigning meaning without use of a confidential process or key, and such confidential process or key that might enable decryption has not been breached, and shall have the meaning given to such term under HIPAA, including 45 CFR § 164.304.
 - 1.8 “HIPAA”** shall mean Health Insurance Portability and Accountability Act, as modified and amended, and its implementing regulations, and incorporating any amendments thereto made by the HITECH Act, GINA, and any other applicable laws or regulations.
 - 1.9 “HITECH Act”** shall mean the Health Information Technology for Economic and Clinical Health Act, found in Title XIII of the American Recovery and Reinvestment Act of 2009, enacted February 17, 2009, and any implementing regulations or guidance thereunder.

**BOSTON SCIENTIFIC CORPORATION
BUSINESS ASSOCIATE AGREEMENT**

- 1.10 “**Individual**” shall have the same meaning as the term "individual" in 45 CFR § 160.103 and shall include a person who qualifies as a personal representative in accordance with 45 CFR § 164.502(g).
- 1.11 “**Protected Health Information**” or “**PHI**” shall have the meaning set forth in 45 CFR § 164.103, limited, however, to the information that Boston Scientific creates, accesses, or receives on behalf of Provider for purposes of Boston Scientific’s provision of Reimbursement Assistance.
- 1.12 “**Privacy Rule**” shall mean the privacy regulations at 45 CFR Part 160 and 45 CFR Part 164, Subparts A and E, as they exist now or as they may be amended.
- 1.13 “**Secretary**” shall mean the Secretary of the Department of Health and Human Services or his designee.
- 1.14 “**Security Rule**” shall mean the security regulations at 45 CFR Part 160 and 45 CFR Part 164, Subparts A and C, as they exist now or as they may be amended.
- 1.15 “**Unsecured PHI**” shall have the meaning assigned to such term in 45 CFR § 164.402, limited, however, to the information that Boston Scientific creates, accesses, or receives on behalf of Provider.

2. Use and Disclosure Obligations

- 2.1 **Use or Disclosure.** Boston Scientific agrees to use and/or disclose PHI only as permitted or required by this BA Agreement or as Required by Law applicable to Boston Scientific;
- 2.2 **Minimum Necessary.** Boston Scientific will take reasonable efforts to limit requests for, use and disclosure of PHI to the minimum necessary to accomplish the intended request, use or disclosure.
- 2.3 **Safeguards.** Boston Scientific agrees to use appropriate safeguards to prevent use or disclosure of PHI other than as permitted or required by this BA Agreement and will comply with the Security Rule with respect to Electronic PHI that Boston Scientific creates, receives, maintains, or transmits on behalf of Provider.
- 2.4 **Reporting.** Boston Scientific agrees to promptly notify Provider if Boston Scientific has knowledge that PHI has been used or disclosed by Boston Scientific in a manner that violates this BA Agreement.
 - 2.4.1 Boston Scientific agrees to report promptly to Provider any Breach or Security Incident of which Boston Scientific becomes aware as determined by Boston Scientific involving PHI in accordance with the Breach Notification Rule. Boston Scientific shall, following the discovery of a Breach of Unsecured PHI, notify Provider of such Breach without unreasonable delay and in no event later than sixty (60) calendar days after the discovery, including the identification of each Individual whose Unsecured PHI has been, or is reasonably believed to have been, accessed, acquired or disclosed during the Breach. A Breach shall be treated as discovered as of the first day on which such Breach is known or reasonably should have been known by Boston Scientific.
 - 2.4.2 Without in any way intending to limit the generality of the obligation in the foregoing paragraph, the parties to this BA Agreement acknowledge and agree that this section constitutes notice by Boston Scientific to Provider of the ongoing existence and occurrence of attempted but Unsuccessful Security Incidents for which no additional notice to Provider shall be required. Unsuccessful Security Incidents shall include, but not be limited to, pings and other broadcast attacks on Boston Scientific’s firewall, port scans, unsuccessful log-on attempts, denials of service and any combination of the above, so long as no such incident results in unauthorized access, use or disclosure of Provider's Electronic PHI.
- 2.5 **Subcontractors and Agents.** Boston Scientific agrees to require all its subcontractors and agents that create, receive, maintain, transmit, use, disclose, or have access to PHI to perform Reimbursement Assistance for Provider to agree, in writing, to no less restrictive restrictions and conditions on the use and/or disclosure of PHI that apply to Boston Scientific, including that all of its subcontractors and agents to whom Boston Scientific provides Electronic PHI agree to comply with the applicable standards of the Security Rule and implement reasonable and appropriate safeguards to protect such

**BOSTON SCIENTIFIC CORPORATION
BUSINESS ASSOCIATE AGREEMENT**

Electronic PHI. If Boston Scientific becomes aware of a pattern of activity or practice of a subcontractor that constitutes a material violation of the subcontractor's obligations under the written agreement described above, Boston Scientific agrees to take reasonable steps to cure or end the violation, and if such steps are unsuccessful, to terminate the agreement if feasible.

- 2.6 Accountability.** Boston Scientific agrees to make internal practices, books, and records relating to the use and disclosure of PHI received from, or created or received by Boston Scientific on behalf of the Provider available to the Secretary upon request in a time and manner directed by the Secretary for purposes of the Secretary determining the Provider's compliance with HIPAA.
 - 2.7 Access and Correction.** To the extent Boston Scientific maintains the requested PHI as part of a Designated Record Set, access shall be provided to Provider to PHI in a Designated Record Set in order to meet the requirements under 45 CFR § 164.524 within fifteen (15) business days of a request. All requests directly from an Individual shall be directed by Boston Scientific to the Provider. If Provider requests that access be provided to an Individual, Boston Scientific shall provide access to the Individual to PHI in a Designated Record Set in a time and manner necessary to meet the requirements under 45 CFR § 164.524. Within sixty (60) days of a request by the Provider or subject Individual, to the extent Boston Scientific maintains the requested PHI as part of a Designated Record Set, Boston Scientific agrees to make any appropriate amendment(s) or correction(s) to PHI in a Designated Record Set that Provider directs or agrees to pursuant to 45 CFR § 164.526.
 - 2.8 Accounting.** Boston Scientific agrees to document and make available to Provider, for a reasonable cost-based fee (under conditions permitted by HIPAA if an Individual requests an accounting more than once during a twelve month period), such disclosures of PHI and information related to such disclosures necessary to respond to the request for an accounting of disclosures of PHI, in accordance with 45 CFR § 164.528 within thirty (30) days of a request by the Provider. Within sixty (60) days of request by Individual, Boston Scientific agrees to make available to the Individual the information described above.
 - 2.9 Mitigation.** Boston Scientific agrees to mitigate, to the extent practicable, any harmful effect that is known to Boston Scientific of a use or disclosure of PHI by Boston Scientific in violation of this BA Agreement.
 - 2.10 Restrictions on Use or Disclosure.** Within fifteen (15) business days of a request of the Provider, Boston Scientific agrees to implement restrictions on the use or disclosure of PHI agreed to by the Provider at the request of an Individual in accordance with 45 CFR § 164.522.
 - 2.11 Remuneration in Exchange for PHI.** Except as permitted under 45 CFR § 164.502(a)(5)(ii), Boston Scientific agrees that it shall not directly or indirectly receive remuneration in exchange for PHI from or on behalf of the recipient of such PHI.
- 3. Permitted Uses and Disclosures of PHI.** Unless otherwise limited herein, in addition to any other uses and/or disclosures permitted or required by this BA Agreement or required by law, Boston Scientific may:
- 3.1** make any and all uses and disclosures of PHI necessary to provide Reimbursement Assistance to Provider;
 - 3.2** use the PHI in its possession for its proper management and administration and to fulfill any legal responsibilities of Boston Scientific;
 - 3.3** disclose the PHI in its possession to a third party for the purpose of Boston Scientific's proper management and administration or to fulfill any legal responsibilities of Boston Scientific; provided, however, that the disclosures are Required by Law or Boston Scientific has received from the third party written assurances that (i) the information will be held confidentially and used or further disclosed only as Required by Law or for the purpose for which it was disclosed to the third party; and (ii) the third party will notify Boston Scientific of any instances of which it becomes aware in which the confidentiality of the information has been breached;

**BOSTON SCIENTIFIC CORPORATION
BUSINESS ASSOCIATE AGREEMENT**

- 3.4 perform Data Aggregation for the Health Care Operations of Provider;
- 3.5 de-identify any and all PHI created or received by Boston Scientific under this BA Agreement; provided, however, that the de-identification conforms to the requirements of the Privacy Rule. Such resulting de-identified information would not be subject to the terms of this BA Agreement; and
- 3.6 may use the PHI to create Limited Data Sets consistent with the requirements of 45 CFR § 164.514(e)(2) of the Privacy Rule (“LDS”). Boston Scientific may use or disclose the LDS only for the limited purposes of Research, Public Health, or Health Care Operations, and the LDS will include only the minimum data fields necessary to accomplish these limited purposes. Boston Scientific will comply with this BA Agreement with respect to the use and disclosure of the LDS.

4. Responsibilities of Provider. Provider agrees:

- 4.1 to obtain any consent, authorization or permission that may be required by the Privacy Rule or any other applicable federal, state or local laws and/or regulations prior to furnishing PHI to Boston Scientific and will notify Boston Scientific of any changes in, or revocation of, permission by an Individual to use or disclose PHI, to the extent that such changes may affect Boston Scientific’s use or disclosure of PHI.
- 4.2 to inform Boston Scientific of any PHI that is subject to any arrangements permitted or required of Provider under the Privacy Rule that may materially impact in any manner the use and/or disclosure of PHI by Boston Scientific under this BA Agreement, including, but not limited to, restrictions on the use and/or disclosure of PHI as provided for in 45 CFR § 164.522 and agreed to by Provider;
- 4.3 to notify Boston Scientific of any limitation(s) in the notice of privacy practices of the Provider in accordance with 45 CFR § 164.520, to the extent that such limitation may affect Boston Scientific’s use or disclosure of PHI.
- 4.4 to not request that Boston Scientific use or disclose PHI in any manner that would exceed that which is minimally necessary under HIPAA or that would not be permitted by Provider;
- 4.5 to the extent required, to have entered into "Business Associate Agreements" with any third parties to which Provider directs and authorizes Boston Scientific to disclose PHI; and
- 4.6 prior to using the name or any trademark or tradename of Boston Scientific in any written or oral communication to the public, including any notices provided under HIPAA, to first give Boston Scientific the opportunity to review and comment on the proposed communication.

5. Term and Termination. This BA Agreement will be effective as of the Effective Date and will continue in effect until terminated in accordance with the provisions herein.

- 5.1 **Termination by Provider.** Upon Provider’s determination of a breach of a material term of this BA Agreement by Boston Scientific, Provider will provide Boston Scientific written notice of that breach in sufficient detail to enable Boston Scientific to understand the specific nature of that breach and afford Boston Scientific an opportunity to cure the breach; provided, however, that if Boston Scientific fails to cure the breach within a reasonable time specified by Provider, which shall not be less than thirty (30) days, Provider may terminate this BA Agreement and the Reimbursement Assistance to the extent that the Reimbursement Assistance requires Boston Scientific to create or receive PHI. If Provider terminates this BA Agreement, Boston Scientific will have no continuing obligation to provide any Reimbursement Assistance to the Provider.
- 5.2 **Termination by Boston Scientific.** Without limiting any other termination rights of the parties, upon Boston Scientific’s knowledge of a material breach by the Provider of this BA Agreement, Boston Scientific shall notify Provider of such breach and the Provider shall have thirty (30) days to cure such breach. In the event the Provider does not cure the breach, or cure is infeasible, Boston Scientific shall have the right to immediately terminate this BA Agreement and the underlying Reimbursement

**BOSTON SCIENTIFIC CORPORATION
BUSINESS ASSOCIATE AGREEMENT**

Assistance.

5.3 Return of PHI. Except as provided in the section below, upon termination of this BA Agreement for any reason, Boston Scientific will return or destroy all PHI received from Provider, or created or received by Boston Scientific on behalf of Provider. This provision will apply to PHI that is in the possession of subcontractors or agents of Boston Scientific.

5.4 Protection of PHI. In the event that Boston Scientific determines that returning or destroying the PHI is infeasible, Boston Scientific will notify Provider of the conditions that make return or destruction infeasible. In that event: (i) Boston Scientific will extend the protections of this BA Agreement to such PHI and limit further uses and disclosures of such PHI to those purposes that make the return or destruction infeasible, for so long as Boston Scientific maintains such PHI; and (ii) Provider will comply with its obligations under this BA Agreement with respect to any PHI retained by Boston Scientific after the termination or expiration of this BA Agreement. This section will survive any termination or expiration of this BA Agreement.

6. Indemnification. Each party (the “**Indemnifying Party**”) shall indemnify and hold the other party and its officers, directors, employees and agents (each an “**Indemnified Party**”) harmless from and against any claim, cause of action, liability, damage, cost or expense (“**Liabilities**”) to which the Indemnified Party becomes subject to as a result of third party claims (including reasonable attorneys' fees and court or proceeding costs) brought against the Indemnified Party, which arise as a result of: (i) the material breach of this BA Agreement by the Indemnifying Party; or (ii) the gross negligence or willful misconduct of the Indemnifying Party, except to the extent such Liabilities were caused by the Indemnified Party. A party entitled to indemnification under this Section 6 shall give prompt written notification to the Indemnifying Party of the commencement of any action, suit or proceeding relating to a third party claim for which indemnification is sought, subject to applicable confidentiality constraints. The Indemnifying Party shall be entitled to assume control of the defense of such action, suit, proceeding or claim with competent counsel of its choosing. Indemnification shall not be required if any claim is settled without the Indemnifying Party’s consent, which such consent shall not be unreasonably withheld. NOTWITHSTANDING THE FOREGOING PROVISIONS OF THIS SECTION, IN NO EVENT WILL AN INDEMNIFYING PARTY BE LIABLE TO AN INDEMNIFIED PARTY UNDER CONTRACT, TORT, OR ANY OTHER LEGAL THEORY FOR INCIDENTAL, CONSEQUENTIAL, INDIRECT, PUNITIVE, OR SPECIAL LOSSES OR DAMAGES OF ANY KIND.

7. Miscellaneous.

7.1 Amendment. The parties acknowledge that the foregoing provisions are designed to comply with the mandates of HIPAA. Boston Scientific may amend this BA Agreement from time to time to the extent that any changes or amendments to HIPAA require changes to this BA Agreement by providing electronic notice of the amended BA Agreement and by posting an updated version of the BA Agreement on the Boston Scientific website. The BA Agreement shall be automatically amended to incorporate the changes set forth in such amendment provided by Boston Scientific to Provider, unless Provider objects to such amendment in writing within fifteen (15) days of receipt of such written notice. In the event that Provider objects timely to such amendment, the parties shall work in good faith to reach agreement on an amendment to the BA Agreement that complies with the changes to the HIPAA regulations. If the parties are unable to reach agreement regarding an amendment to the BA Agreement within thirty (30) days of the date that Boston Scientific receives any written objection from the Provider, either Boston Scientific or Provider may terminate this BA Agreement upon ninety (90) days written notice to the other party. Any other amendment to this BA Agreement unrelated to compliance with applicable law and regulations shall be effective only upon execution of a written agreement between the parties.

7.2 No Third-Party Beneficiaries. Nothing expressed or implied in this BA Agreement or any associated agreement between the parties is intended to confer, nor shall anything herein confer, upon any person other than the parties and the respective successors or assigns of the parties, any rights, remedies,

**BOSTON SCIENTIFIC CORPORATION
BUSINESS ASSOCIATE AGREEMENT**

obligations or liabilities whatsoever.

- 7.3 Severability.** If any provision of this BA Agreement is found invalid or unenforceable by a court of competent jurisdiction, the remaining portions will remain in full force and effect.
- 7.4 Waiver.** No failure or delay by either party in exercising any right hereunder will operate as a waiver thereof.
- 7.5 Assignment.** If a party wishes to assign or otherwise transfer this BA Agreement, or any of its rights or obligations hereunder, to anyone, such party must obtain the other's prior written consent, which will not be unreasonably withheld provided that it will be reasonable to withhold consent if the assignee is a competitor of the non-assigning party. Boston Scientific may assign this BA Agreement, or any of its rights or obligations hereunder, to any of its affiliates without any notice to or consent of Provider. Any attempted assignment or transfer not expressly permitted by the foregoing will be void. This BA Agreement will be binding on the parties, their successors and permitted assigns.
- 7.6 Interpretation.** Any ambiguity in this BA Agreement shall be resolved in favor of a meaning that permits the Provider and Boston Scientific to comply with HIPAA and be construed in light of any applicable interpretation or guidance on HIPAA, the Privacy Rule, the Security Rule, and/or the Breach Notification Rule issued by HHS or the Office for Civil Rights.
- 7.7 Contradictory Terms.** The parties agree that any provision of any other agreement between the parties, including any other business associate agreement, regardless of when executed, which concerns the parties' exchange of PHI and which contradicts one or more terms of this BA Agreement, or which would have the effect of diminishing a right, increasing a duty, or shortening a deadline applicable to Boston Scientific under this BA Agreement (collectively, a "**Contradictory Term**"), shall be superseded by the terms of this BA Agreement unless Boston Scientific expressly waives such superseding effect in a separately written agreement referencing this section.
- 7.8 Notices.** All notices pursuant to this BA Agreement must be given in accordance with the following. If to Boston Scientific, by postal mail to 300 Boston Scientific Way, Marlborough, MA 01752, Attn: Reimbursement Assistance or by facsimile to 1-877-835-2520. If to Provider, by address or facsimile on record with Boston Scientific's Reimbursement Assistance.
- 7.9 Effective Date.** This BA Agreement shall be effective as of the provision of Reimbursement Assistance by Boston Scientific to Provider; provided, however, that any term or condition that relates to obligations of either party only will be effective on the later of the effective date of this BA Agreement or the compliance date applicable to such obligations under HIPAA.
- 7.10 Signatures.** This Agreement may be executed in one or more counterparts, each of which shall be deemed an original, but all of which together shall constitute the same instrument. An electronic signature or scanned and emailed signature shall be deemed an original signature for all purposes hereunder.

Authorized Office Representative: _____ **Date:** _____

Signing on behalf of: _____

Boston Scientific Corporation: _____

Sergio Del Olmo, Director, Reimbursement Operations